Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells.

Literature DB >> 8723485

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells.

Abstract

Penciclovir [9-(4-hydroxy-3-hydroxymethylbut-1-yI)guanine], an effective antiherpesvirus agent, was found to be a potent and selective antiviral agent against intracellular hepatitis B virus (HBV) replication (drug concentration at which a 10-fold decrease in HBV DNA from the average level in an untreated culture was observed [EC90], 1.6 microM) and extracellular virion release (EC90, 0.7 microM) by cultured human hepatoblastoma (2.2.15) cells. Acyclovir and three other related 9-alkoxypurines with activity against either herpesviruses or human immunodeficiency virus were uniformly inactive against HBV. The activity of penciclovir is discussed in relation to recent findings related to its mode of action against HBV.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1996 PMID： 8723485 PMCID： PMC163310 DOI： 10.1128/AAC.40.5.1282

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

14 in total

1. A cell culture assay for compounds which inhibit hepatitis B virus replication.

Authors: B E Korba; G Milman
Journal: Antiviral Res Date: 1991 Mar-Apr Impact factor: 5.970

2. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus.

Authors: B Lee; W X Luo; S Suzuki; M J Robins; D L Tyrrell
Journal: Antimicrob Agents Chemother Date: 1989-03 Impact factor: 5.191

3. Controlled clinical trial of acyclovir in chronic hepatitis B virus infection.

Authors: G J Alexander; E A Fagan; J E Hegarty; J Yeo; A L Eddleston; R Williams
Journal: J Med Virol Date: 1987-01 Impact factor: 2.327

4. Synthesis and antiviral activity of 9-alkoxypurines. 1. 9-(3-Hydroxypropoxy)- and 9-[3-hydroxymethyl)propoxy]purines.

Authors: M R Harnden; P G Wyatt; M R Boyd; D Sutton
Journal: J Med Chem Date: 1990-01 Impact factor: 7.446

5. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action.

Authors: D D Ilsley; S H Lee; W H Miller; R D Kuchta
Journal: Biochemistry Date: 1995-02-28 Impact factor: 3.162

6. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.

Authors: D L Earnshaw; T H Bacon; S J Darlison; K Edmonds; R M Perkins; R A Vere Hodge
Journal: Antimicrob Agents Chemother Date: 1992-12 Impact factor: 5.191

7. Acyclovir, oral, intravenous and combined with interferon for chronic HBeAg-positive hepatitis.

Authors: S W Schalm; R A Heytink; H R Van Buuren; R A De Man
Journal: J Hepatol Date: 1986 Impact factor: 25.083

8. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers.

Authors: M A Pue; S K Pratt; A J Fairless; S Fowles; J Laroche; P Georgiou; W Prince
Journal: J Antimicrob Chemother Date: 1994-01 Impact factor: 5.790

9. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions.

Authors: M A Sells; A Z Zelent; M Shvartsman; G Acs
Journal: J Virol Date: 1988-08 Impact factor: 5.103

10. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.

Authors: K N Tsiquaye; M J Slomka; M Maung
Journal: J Med Virol Date: 1994-03 Impact factor: 2.327

15 in total

Review 1. Treatment of chronic hepatitis B: new antiviral therapies.

Authors: F Yao; R G Gish
Journal: Curr Gastroenterol Rep Date: 1999 Feb-Mar

2. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors: W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal: Antimicrob Agents Chemother Date: 2001-06 Impact factor: 5.191

Review 3. Mitochondrial injury. Lessons from the fialuridine trial.

Authors: P Honkoop; H R Scholte; R A de Man; S W Schalm
Journal: Drug Saf Date: 1997-07 Impact factor: 5.606

4. An experiment on standardized cell culture assay in assessing the activities of Composite Artemisia Capillaris Tablets against hepatitis B virus replication in vitro.

Authors: Jin Han; Yan-ling Zhao; Li-mei Shan; Feng-jiao Huang; Xiao-he Xiao
Journal: Chin J Integr Med Date: 2005-03 Impact factor: 1.978

5. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors: S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191

Review 6. Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors: B Jarvis; D Faulds
Journal: Drugs Date: 1999-07 Impact factor: 9.546

7. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.

Authors: L Fu; Y C Cheng
Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191